# Rasburicase (Fasturtec) Registration Trial

> **NCT00607152** · PHASE3 · TERMINATED · sponsor: **Sanofi** · enrollment: 10 (actual)

## Conditions studied

- Hyperuricemia

## Interventions

- **DRUG:** Rasburicase
- **DRUG:** Allopurinol

## Key facts

- **NCT ID:** NCT00607152
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-10
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** the patient enrollment is too difficult
- **Last updated:** 2014-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00607152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00607152, "Rasburicase (Fasturtec) Registration Trial". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00607152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*